For this purpose, a selective radiolabeled ligand is used targeting prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein avidly expressed on the surface of prostate cancer cells [2, 3]. This evidence concerns the gene FOLH1 and prostate carcinoma.